Source: Simply Better Brands Corp.
  • Common shares of Simply Better Brands are now trading on the OTCQB under the symbol PKANF
  • The company will continue to trade on the TSXV under its current symbol
  • More than 10,000 companies trade on OTC (over-the-counter) markets
  • Simply Better Brands Corp. leads an omnichannel platform with assets in the plant-based and holistic wellness categories
  • Simply Better Brands Corp. (SBBC) opened trading at C$5.15 per share

Simply Better Brands (SBBC) is now trading on the OTCQB under the symbol PKANF. 

The company will continue to trade on the TSXV under its current symbol.

SBBC’s largest market is in the United States. The company is expanding into Latin America, Mexico, the UK and parts of South America. 

More than 10,000 companies trade on OTC (over-the-counter) markets. Developing international companies often enter the U.S. stock market through an OTC listing. Eligible companies must be current in reporting and undergo annual verification.

Brian Meadows, CFO of SBBC commented on the listing.

“We are pleased to announce our listing on the OTCQB markets. This accomplishment will expand access to shares in the company tremendously for US investors.”

Simply Better Brands Corp. leads an international omnichannel platform with diversified assets in the emerging plant-based and holistic wellness consumer product categories. The company continues to focus on expansion into high-growth consumer product categories including CBD products.

Simply Better Brands Corp. (SBBC) opened trading at C$5.15 per share.

More From The Market Online

Odd Burger to add 40 locations in Florida

Odd Burger (TSXV:ODD) will develop 40 new locations in Florida over the next eight years, with its sights set on further U.S. expansion.

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.